Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

SCH 420814

Known as: SCH-420814, SCH420814 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Among the class A G protein-coupled receptors (GPCR), the human adenosine A2A receptor (hA2AAR) represents an attractive drug… Expand
2013
2013
The effects of standard adenosine receptor (AR) agonists and antagonists on the proliferation of human T lymphocytes… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
Review
2013
Review
2013
Preladenant (SCH 420814) is a potent selective antagonist at the adenosine A2A receptor that is being studied for treatment in… Expand
2012
2012
What is known and Objective:  Preladenant (SCH420814, MK‐3814) is a highly selective orally bioavailable non‐methylxanthine… Expand
Review
2011
Review
2011
  • S. Factor
  • Neurotherapeutics
  • 2011
  • Corpus ID: 9910444
SummarySymptomatic medical therapies for Parkinson’s disease (PD) have been disease modifying and have led to improvement in… Expand
  • table 1
  • table 3
Highly Cited
2011
Highly Cited
2011
Striatal adenosine A2A receptors (A2ARs) are highly expressed in medium spiny neurons (MSNs) of the indirect efferent pathway… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Review
2011
Review
2011
In the past few decades, medicinal chemistry research towards potent and selective antagonists of human adenosine receptors… Expand
  • table 1
  • table 1
  • figure 1
  • figure 1
  • figure 2
2010
2010
Parkinson's disease (PD) is a very serious neurological disorder, and current methods of treatment fail to achieve long-term… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
Antagonism of the adenosine A(2a) receptor offers great promise in the treatment of Parkinson's disease. In the course of… Expand
Highly Cited
2007
Highly Cited
2007
Antagonism of the adenosine A2A receptor offers great promise in the treatment of Parkinson's disease. Employing the known… Expand